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Background: Our aim was to determine and characterize S. aureus (SA) isolated from infections in newborns for
antibiotic resistance, virulence factors, genotypes, epidemiology and antibiotic consumption.
Methods: Prospective surveillance of infections was conducted. Data about antibiotic treatment were analyzed.
Antimicrobial susceptibility was assessed. PCR amplification was used to detect resistance and virulence genes.
Typing methods such as PFGE, spa-typing and SCCmec were used.
Results: SA was found to be associated with 6.5% of infections. Methicillin-Resistant Staphylococcus aureus
accounted for 32.8% of SA-infections. An incidence of MRSA-infections was 1.1/1000 newborns. MRSA-infections
were diagnosed significantly earlier than MSSA-infections in these newborns (14th day vs. 23rd day (p = 0.0194)).
MRSA-infections increased the risk of newborn’s death. Antibiotic consumption in both group was similar, but a
high level of glycopeptides-usage for MSSA infections was observed.
In the MRSA group, more strains were resistant to erythromycin, clindamycin, gentamicin and amikacin than in the
MSSA group. Hla gene was present in 93.9% of strains, and seg and sei in 65.3% of strains, respectively. One
dominant clone was found among the 14 MRSA isolates. Fifteen strains belonging to SCCmec type IV were spa-t015
and one strain belonging to SCCmec type V was spa-t011.
Conclusions: Results obtained in the study point at specific epidemiological situation in Polish NICU (more detailed
studies are recommended).
High usage of glycopeptides in the MSSA infections treatment indicates the necessity of antimicrobial stewardship
improvement and introducing molecular screening for early identification of infections.Background
Systemic infections caused by Staphylococcus aureus
(SA) are still common among newborns in neonatal in-
tensive care units (NICUs) [1]. The danger of S. aureus
is attributed to its resistance to many antibiotics and
high virulence [2]. To our knowledge, there have been
no studies on the epidemiology of SA in patients of* Correspondence: rozanska@ifb.pl
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veillance of such infections in this vulnerable population.
The primary aim of this study was to determine and
characterize S. aureus isolates from newborns according
to resistance, virulence factors, genotypes and epidemi-
ology. Secondly, we assessed the level of antibiotic usage
and possible risk factors for SA infection (separately for
Methicillin-sensitive SA (MSSA) and Methicillin-resistant
SA (MRSA)). These factors included: clinical (use of
devices: central/peripheral venous catheter – CVC/
PVC, mechanical ventilation – MV, continuous positiventral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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TPN, length of stay in hospital until infection, and breast/
trophic feeding) and demographic data.Methods
Utilization of data collected in the Polish Neonatology
Surveillance Network (PNSN) for scientific purposes
was approved by the Bioethics Committee of Jagiellonian
University Medical College – no. KBET/227/B/2012. All
data entered into the electronic database and analyzed
during this study were previously anonymised and de-
identified. The PNSN is a prospective national surveil-
lance system for the most relevant infections in VLBW
infants (with birth weight < 1500 g) in Poland. Details of
the following variables were collected for all VLBW
newborns: birth weight and gestational age, gender, mul-
tiple pregnacy, type of delivery and information of the
situation in time of delivery, for example chorioamnioni-
tis, general status of newborns by Apgar score: at 1 and
5 minutes and Critical Risk Index for Babies, CRIB) and
others. Participation in PNSN is voluntary and confiden-
tial, the surveillance covered over 20% of VLBW infants
born in the regions where the NICUs were located.Study population
Prospective surveillance of infections was conducted
between 2009–2012 at five tertiary academic NICUs
that lead the perinatal care, in hospitals (designed by
letters A, B, C, E, F) that participated in the PNSN,
and included 1768 newborns. The labor of 135 newborns
was complicated by chorioamnionitis, while 429 infants
were delivered after premature rupture of membranes
(PROM). All episodes of infection were subjected to re-
cording, regardless of the time of occurrence of the first
symptoms. Case patients were defined according to
Gastmeier et al. [3] with modification, as very low
birth weight (VLBW) neonates who demonstrated clin-
ical signs and/or symptoms of bloodstream infection
(BSI) or pneumonia.
Early-onset infection was defined as infection diag-
nosed within 3 days after delivery. Device-associated in-
fection was defined as infection diagnosed in newborns
who had a device (central/peripheral venous catheter or
mechanical ventilation or continuous positive airway
pressure) placed within the 48-hour period before infec-
tion onset. Device utilization ratio (calculated by divid-
ing the number of days with devices by the total number
of patient/days, pds) was: 0.41 for CVC, 0.21 for PVC,
0.38 for MV, 0.28 for CPAP and 0.47 for TPN.
SA-infection was defined as culture-proven infection
with isolation of SA. MSSA (or MRSA) infection was de-
fined as culture-proven infection with isolation of MSSA
(or MRSA).Bacterial isolates
Collecting and identifying bacterial strains were performed
in the local microbiology laboratories. Various diagnostic
specimens were collected for culture and assessment of the
microbial aetiology of infections. Altogether, 58 SA strains
were isolated – and were considered to be the aetiological
factor of infection. In this group, 49 strains were used for
further analysis: most were from cases of pneumonia (20)
and from BSI (19); nine were not stored. Strains in
local laboratory were stored in −20°C, in laboratory of
Chair of Microbiology were stored in −70°C. Isolates
were identified by the automated identification system
(VITEK 2, bioMerieux, Poland).
Susceptibility testing
All strains were tested using disk diffusion antimicrobial
susceptibility methods according to current guidelines of
the European Committee on Antimicrobial Susceptibility
Testing (Clinical breakpoints tables v. 3.1; http://www.
eucast.org v.3.1). E-tests for vancomycin and teicoplanin
(bioMérieux, Paris, France) were also performed for all
the isolates.
The MRSA resistance phenotype was detected using a
cefoxitin disc (30 μg) according to the EUCAST guidelines.
The macrolide-lincosamide (MLS) resistance phenotype of
the isolates was determined according to a previously pub-
lished protocol [4].
DNA isolation
DNA was extracted from isolates using the Genomic
Mini kit (A&A Biotechnology, Gdynia, Poland) accord-
ing to the manufacturer’s instructions.
Polymerase chain reaction (PCR) screening for resistance
genes
PCR amplification was used to detect the mecA gene
using previously published primers [5]. As controls,
S. aureus ATCC 33591 (mecA+) and S. aureus ATCC
25923 (mecA−) were employed. Erythromycin resist-
ance genes (ermA, ermB, ermC, and msr) were detected
by multiplex PCR, and amplification of a 456 bp fragment
of the mupA gene (mupirocin resistance gene) was per-
formed by single PCR [6,7].
Antibiotic treatment
Data about antibiotic treatment were entered into the
database by the ward personnel based on the physicians’
orders. Precise information about the type of drug, daily
dose, and length of treatment for each antibiotic was
collected and used for the calculation of two indicators:
duration of treatment and defined daily dose in refer-
ence to each case of infection.
The aggregate sum of the number of days during
which at least one dose of antibiotic was received for
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expressed in days and the defined daily dose (DDD),
according to the ATC/DDD system of the World Health
Organization (Anatomical Therapeutic Chemical, group
“J01”). Only antibiotics for systemic use were taken into
account.
Antibiotic usage for treatment (until cure) was assessed
for 56 cases; two cases were excluded from analysis due to
death of the infant within the first seven days of illness
(unsuccessful treatment) and lack of data on treatment of
one newborn.
Virulence factor screening
S. aureus isolates were checked for the presence of se-
lected virulence genes: tsst (toxic shock syndrome toxin),
sea, seb, sec, seg, seh, sei, sej (staphylococcal enterotoxins
A, B, C, G, H, I, J), eta, etb (exfoliative toxins A and B),
lukE (LukDE leucocidin), pvl (Panton-Valentine leucoci-
din, and hla (staphylococcal alpha haemolysin) using
PCR with previously published primers [8-10]. The fol-
lowing S. aureus strains were used as positive controls:
2535/07 (eta+, etb+, seg+, sei+), 8977/99 (sea+, sec+,
seg+, sei+), 6616/09 (seb+, tsst+, pvl+), 2027/06 (sea+,
seh+), and 1034/05 (sea+, seg+, sei+, sej+). The strains
used as controls were kindly provided by Prof. Marek
Gniadkowski, National Medicines Institute, Warsaw,
Poland.
Pulsed-Field Gel Electrophoresis (PFGE)
Analysis of the genetic similarity between SA isolates
was performed by PFGE method in accordance with a
previously published protocol [11]. Restriction enzyme
digestion was performed with 25 U of SmaI enzyme in
Tango buffer (ThermoScientific, USA). Electrophoresis
was conducted in a CHEFIII PFGE unit applying the pa-
rameters: block 1- starting pulse 5 s, ending pulse 12 s,
voltage 6 V/cm, run time 11 h, block 2- starting pulse
20s, ending pulse 60 s, voltage 6 V/cm, run time 13 h.
The GelCompar (Applied Maths, Sint-Martens-Latem,
Belgium) was used for cluster analysis using the Dice coef-
ficient and unweighted pair group method with arithmetic
mean. Isolates that clustered ≥ 95% were considered as an
epidemic clone. S. aureus strain ATCC 11632 was used as
reference.
Spa sequencing
spa typing was performed as described previously [12],
using the spa typing website (http://www.spaserver.
ridom.de/) that was developed by Ridom GmbH (Mün-
ster, Germany).
SCCmec typing
Staphylococcal cassette chromosome mec (SCCmec) typing
was performed as described previously [13]. The followingS. aureus strains were used as positive controls: ATCC-
BAA 1762 (SCCmec IV), ATCC-BAA 2094 (SCCmec V),
and ATCC-BAA 1681 SCCmec II).Statistical methods
The statistical analysis was based on two main groups of
techniques. Comparison of the ratio of MSSA/MRSA
was performed with a contingency test supplemented by
odds ratio analysis. To determine the relationship be-
tween continuous and categorical variables, Student’s
T test and ANOVA were used. If the distribution of
the continuous variable did not fit a normal distribution,
the analysis was conducted with nonparametric equiv-
alents of parametric tests: Wilcoxon test for Student’s
T test, and Kruskal-Wallis test for ANOVA. The rela-
tionship between two continuous variables was ana-
lyzed with Pearson Regression or its non-parametric
alternatives. Because of the categorical nature of the
effect and combined – numeric as well as categorical –
types of predictors, the model was constructed for binom-
inal distribution of dependent variables and the logit-
linked function. P-values of <0.05 were considered to be
statistically significant.Results
The total number of SA infection was 58 cases, these
the incidence of SA-infections was 3.3% and 1.0/1,000
pds. The incidence of MRSA infections (19 cases) was
1.1%. No significant association was found between time
of hospitalization in NICU and the risk of MRSA.
The number of MRSA infections in the group of SA-
infections – proportion was 32.8 (range from 8.3% to
42.1% in different centers). The most common SA-
infections were BSI (55.2%) and pneumonia (39.7%).
MRSA was observed more often among BSI, statis-
tical significance was not observed but a strong trend
was noted MRSA (p = 0.0515; odds ratio, OR 2.2807,
95% Confidence Interval, CI 0.7198–7.2265). MRSA
was not associated with a central/peripheral line cath-
eter (p = 0.8085, OR 0.963, 95% CI 0.2952–3.1417).
All SA-infections were diagnosed on average at day 21 of
stay, (median: 17th day). MRSA-infections were diagnosed
significantly earlier than MSSA-infections, on average 14th
day vs. 23rd day; there was no relationship between the use
of devices and prevalence of SA-infections (either MSSA
or MRSA).
The fatality case rate was higher among newborns with
MRSA infection than with MSSA infection (10.5% vs.
0.0%). The gestational age, birth weight, and other fac-
tors of newborns with MRSA was similar to those with
MSSA (Table 1).
Multivariate analysis also showed no association be-
tween the ward studied, phenotype of the isolate of
Table 1 Characteristics of newborns with SA-infections
Infants with MSSA-infections
[N = 39]
Infants with MRSA-infections
[N = 19]
P-value
Risk factors of patients average (95%CI) average (95%CI)
Birth weight [grams] 873.7 (791.0–956.5) 948.3 (817.3–1079.4) 0.304
Gestational age [weeks] 27.7 (26.8–28.6) 27.2 (25.6–28.8) 0.316
CRIB 5.5 (3.5–7.5) 2.4 (1.9–6.8) 0.049
Apgar (1 min.) 4.9 (4.3–5.6) 4,7 (3.7–5.8) 0.860
Apgar (5 min.) 6.2 (5.6–6.8) 6.0 (4.8–7.2) 0.817
length of stay in hospital [days] 56.2 (49.1–63.2) 48.4 (37.1–59.8) 0.197
length of hospital stay until infection [days] 23.8 (19.7–28.5) 14.7 (9.8–19.7) 0.019
DOT 11.2 (9.6–12.7) 12.3 (7.7–16.8) 0.885
DDD 30.2 (22.6–37.8) 26.0 (16.4–33.5) 0.457
Risk factors of patients number (%) number (%) OR (95%CI) P-value
Female gender 19 (48.7) 7 (36.8) 0.614 (0.200–1.889) 0.393
Breast feeding 4 (10.5) 1 (5.6) 0.486 (0.051–4.677) 0.542
Trophic feeding 21 (55.3) 12 (66.7) 1.470 (0.477–4.525) 0.418
Total parenteral nutrition 25 (65.8) 15 (79.0) 2.1 (0.583–7.571) 0.306
Fatal cases 0 (0.0) 2 (10.5) n/a; n/a; 0.039
CRIB, clinical risk index for babies; DOT, the aggregate sum of the number of days during which at least 1 dose of antibiotic was received; DDD, defined daily
dose.
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ation of pregnancy.
Antibiotic treatment
The average antibiotic consumption was similar between
MSSA and MRSA cases. The DOT average was 11.2 for
MSSA cases and 12.3 for MRSA cases; the DDDs were
equal between the groups (30.2 and 26.0, respectively,
Table 1). However, statistically significant differences
were observed in DOT between the studied wards (ward
B was significantly shorter than ward E, p = 0.002) and
in DDD (ward F had lower consumption than ward A,Table 2 Distribution of individual antibiotic groups usage in
Antibiotic groups DOT [%] OR (95%C
MRSA MSSA
Aminoglycosides 17.2 14.9 0.976 (0.69
Beta-lactams 6.3 31.7 0.146 (0.09
Fluoroquinolones 6.0 0.0 n/a
Glycopeptides 63.6 43.0 2.296 (1.76
Lincozamides 2.7 1.1 2.562 (1.00
Macrolides 4.2 5.8 0.723 (0.39
Trimethoprim/sulfamethoxazole 0.0 3.0 n/a
Metronidazole 0.0 0.5 n/a
Total 100.0 100.0
OR, odds ratio; 95%CI, 95% Confidence Interval; DOT, the aggregate sum of the num
defined daily dose; n/a not applicable.p = 0.0049). There were no significant differences be-
tween DDD and length of therapy of SA-infections de-
pending on phenotype (MRSA vs. MSSA).
Antibiotics used most often for treatment of SA infec-
tions (both methicillin-susceptible and –resistant; Table 2)
were glycopeptides, beta-lactams and aminoglycosides.
For beta-lactams DOT values were significantly higher for
MSSA than for MRSA (Z = −2.77787, p = 0.0052; MRSA
mean 3.5; SD 1.37; median 3.5, max 5; for MSSA mean
7.8; SD 4.15; median 7; max 21).
Diagram showing antibiotics consumption in the study
population is presented in Additional file 1.MRSA (18 cases) and MSSA (28 cases) infections
I) P-value DDD [%] OR (95%CI) P-value
MRSA MSSA
7–1.367) 0.967 31.7 28.0 1.366 (1.096–1.704) 0.561
2–0.233) 0.005 19.0 40.9 0.338 (0.264–0.435) 0.879
9.3 0.0 n/a
6–2.985) 0.427 33.4 24.9 1.513 (1.208–1.895) 0.533
8–6.512) 0.221 0.8 1.0 0.775 (0.250–2.408) 0.073
3–1.330) 0.832 2.8 4.4 0.629 (0.348–1.138) 0.072
0.0 0.2 n/a
0.0 0.6 n/a
100.0 100.0
ber of days during which at least 1 dose of antibiotic was received; DDD,
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The MRSA phenotype was found for 16 isolates (32.6%)
and the inducible MLS (iMLS) phenotype was observed in
11 isolates (22.4%). Seven strains exhibited both pheno-
types. Four isolates (8.2%) with M phenotype (resistant to
erythromycin but susceptible to clindamycin) were found.
All strains were susceptible to ofloxacin, vancomycin and
teicoplanin. The MIC50 for vancomycin was 1.5 mg/ml
and for teicoplanin was 1.0 mg/ml.
Molecular characterisation showed that all MRSA iso-
lates carried the mec gene. Only three MLS strains had
erm genes (ermA was found in two isolates and ermB in
one isolate). One strain had the mup gene.
S. aureus isolates were tested for the presence of genes
encoding for virulence factors (VFs). The differences in
distributions of the VFs were analysed. Detailed data are
presented in Table 3: no association was found between
number of VFs and resistance to numbers of antimicro-
bial classes.Table 3 Virulence factors among isolates and resistance to
antimicrobials
Virulence
factor
All [N = 49];
(n, %)
MRSA [N = 16];
(n, %)
MSSA [N = 33];
(n, %)
hla 46 (93.9) 16 (100) 30 (90.9)
sea 8 (16.3) 1(6.3) 7 (21.2)
seb 0 0 0
sec 7 (14.3) 4 (25) 3 (9.1)
seg 32 (65.3) 15 (93.8) 17 (51.5)
seh 1 (2.0) 1 (6.3) 0
sei 32 (65.3) 15 (93.8) 17 (51.5)
sej 4 (8.2) 0 4 (12.1)
eta 7 (14.3) 4 (25) 3 (9.1)
etb 0 0 0
tsst 9 (18.4) 0 9 (27.3)
lukE 19 (38.8) 0 19 (57.6)
pvl 0 0 0
Resistance All [N = 49]; (%) MRSA [N = 16]; (%) MSSA [N = 33]; (%)
E 16 (32.6) 10 (62.5) 6 (18.2)
DA 12 (24.5) 7 (43.7) 5 (15.1)
OFX 0 0 0
GN 3 (6.1) 2 (12.5) 1 (3.0)
TOB 6 (12.2) 2 (12.5) 4 (12.1)
AK 6 (12.2) 3 (18.7) 3 (9.1)
VA 0 0 0
TEC 0 0 0
Legend: E-erythromycin, DA-clindamycin, OFX – ofloxacin, GN – gentamycin,
TOB – tobramycin, AK – amikacin, VA – vancomycin, TEC – teicoplanin.
hla (staphylococcal alpha haemolysin), sea, seb, sec, seg, seh, sei, sej (staphylococcal
enterotoxins A, B, C, G, H, I, J), eta, etb (exfoliative toxins A and B), tsst (toxic shock
syndrome toxin), lukE (LukDE leucocidin), pvl (Panton-Valentine leucocidin).Typing
MSSA isolates showed very different pulsotypes; domin-
ant clones were not detected. Cluster analysis based on
PFGE of the 33 isolates showed 23 pulsotypes, some of
which were less than 70% similar, suggesting a genotypi-
cally variable population. Isolates with identical pulso-
types were usually derived from different patients in the
same NICU during the same period of time. Analysis of
SmaI macro-restriction profiles of the 16 MRSA iso-
lates revealed one dominant clone (14 isolates). The
two remaining MRSA isolates had different PFGE pat-
terns (Figure 1). MRSA isolates belonging to the dom-
inant clone were derived from one NICU designed by the
letter F. Two spa types and two SCCmec were observed:
spa-t015 in the case of 15 isolates belonging to the
SCCmec type IV and spa-t011 in one isolate belonging to
the SCCmec type V.
Discussion
Staphylococcus aureus is still one of the most important
causes of infections in NICU patients, and usually repre-
sents a large part of the aetiology of infection. For example,
in the UK, Vergnano reported a prevalence of about 18%
[14], which was similar to the level in the U.S. [15],
whereas in Germany the prevalence was 10.2% [16]. In the
group of neonates in the present study, SA-infections were
observed 2–3 times less frequently. Similar results have
been obtained in the field of drug resistance, especially
MRSA, in late- and early-onset infections. A number of
multicentre studies, however, found a higher proportion of
MRSA. In Japan, MRSA strains accounted for more than
88% [17] of SA infections, and in Cyprus, 68% [18], of SA
infections.
In contrast, in the US (only in VLBW newborns) the
prevalence of MRSA infection was 0.4% [19], while in
Poland and the UK, it was 1.1% [14]. Furthermore,
according to Vergnano’s data, the proportion of infec-
tions with the MRSA phenotype in late infections was a
little over 10% of SA-infections, which was much less than
in the group examined in the present study [14].
The difference in findings between studies may be due
to the fact that the United Kingdom was one of the first
countries in the world to introduce wide mandatory sur-
veillance of MRSA [20,21]. For example, beginning in
2010, screening for MRSA in most patients admitted for
elective hospital was instituted [22]; this action under-
scores the fact that MRSA colonization was considered
an important risk factor for this aetiology of infection
[23]. Implementation of the UK guidelines resulted in a
reduction of MRSA infections in health care settings in
general [24]. Furthermore, this reduction has had a dir-
ect impact on the prevalence of MRSA in the general
population; thus, the risk of colonization of pregnant
women, young parents and NICU staff also has dropped
Figure 1 Results of PFGE, SCCmec and spa typing of S.aureus isolates.
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often occurs as “community-acquired” infections [25,26].
The fact that there was no relationship between MRSA
infections resulting from invasive procedures and late-
onset MRSA infections should be discussed with special at-
tention. A number of authors pointed to an increasing risk
of infections with multidrug-resistant (MDR) strains during
hospitalisation and resulting from invasive procedures.
Lessa et al. showed that MRSA infections among newbornsobserved most often were late-onset: median age at disease
onset was 28 days [19]. These results suggest that infection
with MDR strains should be also considered at the early
stage of hospitalisation. No relationship between MRSA in-
fections resulting from invasive procedures could be made
with the huge number of invasive procedures among this
group of patients. Hocevar et al. showed that MRSA con-
stituted about 33% of device-associated infections, which is
consistent with the results of this study [27].
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ent of surveillance for drug-resistant strains [28]. The re-
sults of this study reveal the methodological difficulties
associated with the assessment of the consumption of
antibiotics by neonates. In similar studies, other authors
used indicators such as DOT, LOT (the number of days
where at least one dose of any antibiotic was received),
DDD or PDD (prescribed daily dose) [29,30]. In the present
study, there were no significant differences in DOT or
DDD as determined by analysis of the average consump-
tion of all groups of antibiotics used in the treatment of SA
infections. Stratification of antibiotic consumption accord-
ing to individual groups showed, however, that the indica-
tor used, (DOT/DDD), has an impact on significance of the
differences in therapeutic regimens used for MRSA and
MSSA. In case of beta-lactams the level of antibiotic con-
sumption was statistically significantly higher only in case
of assessment with DOT usage. Therefore, analysis of
antibiotic consumption should not be based on only
one parameter, and the data should be stratified in order
to be able to determine meaningful differences [31].
The data about antibiotic consumption show high
usage of glycopeptides in both groups: MRSA-infections
and MSSA-infections, when expressed as DOT. Rapid
diagnostic molecular methods (which enable rapid assess-
ment of the need to implement or discontinue therapy
with vancomycin) should be implemented to decrease gly-
copeptide consumption, because glycopeptides are not
easy to use in neonates [32,33]. On the other hand, the
study of Brzychczy-Włoch et al. showed a high percentage
of Gram-positive mecA-positive infections in NICUs [34].
For this reason vancomycin should not be eliminated from
use among NICUs but effort should be made toward low-
ering the vancomycin consumption.
As expected, the haemolysin gene was present in almost
all studied isolates with occasional exceptions. In contrast,
genes encoding exfoliative toxins were rare: no such
patients were among our study population. The low
frequency of eta and etb coincides with the result of
the other studies [2,35].
In recent years, MRSA producing the Panton-Valentine
leucocidin toxin have emerged as increasingly common
causes of community-acquired infections [36,37]; however,
we did not find pvl-positive isolates, which was similar to
other studies [24].
Of enterotoxin genes detected, those within the egc
(enterotoxin gene cluster) seg + sei were the most fre-
quent (65.3%), which also was shown by Rasmussen
[35]. These enterotoxin genes were found frequently in
isolates from patients but their presence did not mean
the production of toxin was high enough to cause food
poisoning. These superantigens may enhance the persist-
ence of infection but their role as a virulence factors is
still purely speculative [38].Among leucocidins, the prevalence of lukE was rela-
tively high and associated with MSSA but not MRSA
strains. Moreover, the tsst gene was not detected in any of
the MRSA isolates, which was similar to other studies [2].
There have been some studies showing a link between
virulence and resistance [39,40], no such association was
found in this study.
A number of molecular methods have been developed
and implemented for typing MRSA isolates including
SCCmec, PFGE, and spa typing [2]. Most of the MRSA
strains (and only MRSA) isolated in this study belonged
to the epidemic clone: these strains had identical pulso-
types, belonged to the same SCCmec type and spa type,
and came from one of the surveyed centers.
Reports from NICUs showed that it is not easy to deter-
mine the incidence of MRSA-infections. However, results
from the present study, combining detailed epidemio-
logical analyses with molecular studies of SA, allowed a
much broader evaluation of these infections: development,
course and severity of the infection were compared with
resistance and virulence of the strain, and the type of pop-
ulations where they were observed.
Several potential limitations should be considered in
the interpretation of data presented here. First, the num-
ber of isolates investigated was low. Another important
limitation was the lack of a control group – surveillance
was conducted only on a group of very-low birth weight
infants.Conclusions
The key points of results of our study are:
 the MRSA infections were diagnosed significantly
earlier than MSSA-infections (14 vs. 23 day of
hospitalization)
 low proportion of MRSA infections in the group of
SA-infections (32.8%) which additionally were less
frequent than reported in other studies pointing at
specific epidemiological situation in Polish NICU
(more detailed studies are recommended)
 high usage of glycopeptides in the MSSA infections
treatment which indicates the necessity of
antimicrobial stewardship improvement and
introducing molecular screening for early
identification of infectionsAdditional file
Additional file 1: Antibiotics consumption in the study population.Competing interests
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